Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05107674 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
This record was last updated September 9, 2025 (before its estimated August 31, 2026 completion). Its status may not reflect the trial's current state.
Record History
MinorStudy sites: 18 to 17v22
NotablePrimary completion date: Aug 31, 2024 to Aug 31, 2026Study sites: 20 to 18 · Completion date: Feb 28, 2026 to Feb 28, 2028 · Study description expanded, about 21 words · 1 morev21Show 4 more changesShow less
MinorEnrollment target: 363 to 345Study sites: 16 to 17 · Completion date: Feb 28, 2025 to Feb 28, 2026 · Eligibility criteria expanded, about 41 words · 2 morev17Show 5 more changesShow less
MinorEnrollment target: 268 to 363Study sites: 11 to 12 · Interventions: NX-1607 (Drug) to NX-1607 (Drug), Paclitaxel (Drug) · Eligibility criteria expanded, about 52 words · 3 morev13Show 6 more changesShow less
Study sites: 11 to 12
Interventions: NX-1607 (Drug) to NX-1607 (Drug), Paclitaxel (Drug)
MinorEnrollment target: 336 to 268Study sites: 6 to 7 · Eligibility criteria shortened, about 37 words · Study description expanded, about 13 words · 1 morev9Show 4 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.